Johnson & Johnson (NYSE:JNJ) Shares Bought by Canoe Financial LP

Canoe Financial LP boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 92,626 shares of the company’s stock after purchasing an additional 2,900 shares during the period. Canoe Financial LP’s holdings in Johnson & Johnson were worth $13,396,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. IFS Advisors LLC lifted its holdings in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares during the period. Highline Wealth Partners LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at $31,000. RPg Family Wealth Advisory LLC purchased a new stake in Johnson & Johnson during the third quarter worth $35,000. Mowery & Schoenfeld Wealth Management LLC grew its position in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after buying an additional 91 shares during the period. Finally, Activest Wealth Management acquired a new position in shares of Johnson & Johnson in the third quarter worth about $40,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on JNJ shares. Wells Fargo & Company raised their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Wolfe Research assumed coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday. Finally, Royal Bank of Canada upped their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $174.29.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $147.03 on Monday. The firm’s 50-day moving average is $148.51 and its two-hundred day moving average is $156.03. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market capitalization of $353.99 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.37%. Johnson & Johnson’s payout ratio is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.